Qamar Khan

Professor

The University of Kansas Health System
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Year:

2026

Year:

2026

Year:

2025

PURPOSE Neoadjuvant immunotherapy (IO) has become the standard of care for early-stage triple-negative breast cancer (TNBC), but not yet for other subtypes. We previously developed a clinical-grade mRNA-based immune classifier (ImPrint) predicting response to IO that is now being used in I-SPY2.2 as part of the response predictive subtypes. We report the performance of ImPrint in hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+HER2–) patients from five IO arms. METHODS A total of 204 HR+HER2– (MammaPrint high-risk) patients from five IO arms (anti–PD-1, anti–PD-L1/poly [ADP-ribose] polymerase inhibitor combination, anti–PD-1/toll-like receptor 9 dual-IO combination, and anti–PD-1 ± lymphocyte activation gene 3 dual-IO combination) and 191 patients from the chemotherapy-only control arm were included in this analysis. Patients were classified as ImPrint+ (likely sensitive) versus ImPrint– (likely resistant), using pretreatment mRNA. Performance of ImPrint for predicting pathologic complete response (pCR) to IO-containing arms was characterized and compared with tumor grade (III), MammaPrint (ultra) High2 risk (MP2), and estrogen receptor (ER)-low (ER ≤ 10%). RESULTS Overall, the pCR rate across the five IO arms was 33%. 26% of HR+HER2– patients were ImPrint+, and pCR rates with IO were 75% in ImPrint+ versus 17% in ImPrint–, with the highest pCR rate >90% in a dual-IO arm. In the control arm, pCR rates were 33% in ImPrint+ and 8% in ImPrint–. Tumor grade (III), MP2, and ER-low showed pCR rates in IO of 45%, 56%, and 63%, respectively, with lower pCR odds ratios (OR 65%-70%). ImPrint, an Food and Drug Administration IDE-enabled assay, may represent a way to identify HR+HER2– patients for IO that best balances likely benefit versus risk of serious immune-related adverse events.

Year:

2025

Year:

2025

Immune evasion by cancer cells involves reshaping the tumor microenvironment (TME) via communication with non-malignant cells. However, resistance-promoting interactions during treatment remain lesser known. Here we examine the composition, communication, and phenotypes of tumor-associated cells in serial biopsies from stage II and III high-risk estrogen receptor positive (ER+ ) breast cancers of patients receiving endocrine therapy (letrozole) as single agent or in combination with ribociclib, a CDK4/6-targeting cell cycle inhibitor. Single-cell RNA sequencing analyses on longitudinally collected samples show that in tumors overcoming the growth suppressive effects of ribociclib, first cancer cells upregulate cytokines and growth factors that stimulate immune-suppressive myeloid differentiation, resulting in reduced myeloid cell- CD8 + T-cell crosstalk via IL-15/18 signaling. Subsequently, tumors growing during treatment show diminished T-cell activation and recruitment. In vitro, ribociclib does not only inhibit cancer cell growth but also T cell proliferation and activation upon co-culturing. Exogenous IL-15 improves CDK4/6 inhibitor efficacy by augmenting T-cell proliferation and cancer cell killing by T cells. In summary, response to ribociclib in stage II and III high-risk ER + breast cancer depends on the composition, activation phenotypes and communication network of immune cells.

Year:

2025

In early-stage estrogen receptor-positive (ER + ) breast cancer, resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) often involve a shift away from estrogen-driven proliferation. The nature and source of compensatory growth signals driving cancer proliferation remain unknown but represent direct therapeutic targets of resistant cells. By analyzing single-cell RNA-sequencing data from serial biopsies of patient tumors, we elucidated compensatory growth signaling pathways activated in ET + CDK4/6i-resistant cancer cells, along with the intercellular growth signal communications within the tumor microenvironment. In most patient tumors, resistant cancer cells increased ERBB growth pathway activity during treatment, only partially through ERBB receptor upregulation. Concurrently, fibroblasts within the tumor increased ERBB ligand communication with cancer cells, as they differentiated to a proliferative and mesenchymal phenotype in response to TGF $$\beta$$ β signals from cancer cells. In vitro model systems demonstrated molecularly how therapy induces a mutualistic cycle of crosstalk between cancer cells and fibroblasts, fostering a growth factor-rich tumor microenvironment circumventing estrogen reliance. We show that ERBB inhibition can break this cancer-fibroblasts mutualism, targeting an acquired sensitivity of resistant cancer cells.

Year:

2025

Background: Human epidermal growth factor receptor 2 (HER-2) is overexpressed in 15-20% of breast cancer (BC). Pathologic complete response (pCR) after HER-2 directed chemotherapy is an important surrogate marker for survival in HER-2+ operable BC. Patients with diabetes who receive metformin have a lower risk of metastasis in HER-2+ breast cancer. Metformin’s inhibition of PI3K/AKT/mTOR pathway through IGF receptor inhibition has been proposed as a possible mechanism. However, its clinical benefit as an anticancer agent is not clear. We conducted a randomized, placebo-controlled study to assess the impact of adding metformin or placebo to neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCH-P) in HER2 positive breast cancer. Methods: Patients with HER-2+ operable breast cancer with at least 2 cm breast primary and/or axillary lymph node positive disease were eligible. HER-2 positivity was defined by the current ASCO-CAP guidelines. Patients were randomized 1:1 to receive neoadjuvant TCH-P every 3 weeks for 6 cycles, plus placebo (N=30) or metformin (N=31). Metformin dose was ramped up over the first 3 cycles to a target of 1500 mg twice daily on days 8-21 of each cycle. Breast surgery was performed 3-6 weeks after final chemotherapy cycle. The primary endpoint was pCR in breast and axilla. Subjects with unevaluable pCR were treated as non-responders for intent-to-treat analyses. Results: 61 patients were enrolled between 8/17/2017 and 03/21/2023. Median age was 51 years. 51% of the patients had node positive disease and 67% had estrogen receptor (ER) positive breast cancer. Among all patients pCR in both breast and axilla was 43.3% in TCH-P plus placebo group and 54.8% in the metformin group (p= 0.37). In patients with ER+ breast cancer pCR was 42.9% in placebo group and 40.0% in metformin group (p=0.85). Grade ≥3 adverse events occurred in 40% of placebo subjects and 48% of metformin subjects. Grade 3 diarrhea occurred in 29% of the patients in the metformin group compared to 17% in the placebo group. Conclusions: Metformin added to TCH-P neoadjuvant chemotherapy does not significantly improve pCR rate in HER-2+ breast cancer. Grade ≥3 diarrhea was greater in the metformin group. Citation Format: Maire Okoniewski, Cory Bivona, Colleen Bohnenkamp, Francisco Diaz, Junqiang Dai, Lauren Nye, Anne O'Dea, Kelsey Larson, Deepti Satelli, Jamie Wagner, Christa Balanoff, Lyndsey Kilgore, Stephanie Lafaver, Jamie Heldstab, Priyanka Sharma, Qamar Khan. A Randomized Phase II Trial of Neo-adjuvant Chemotherapy with Metformin or Placebo for HER-2 Positive Operable Breast Cancer (The HERMET Trial) [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-11-17.

Year:

2025

Background: Combinations of endocrine therapy and CDK4/6 inhibitors (CDK4/6i) used in metastatic breast cancer (MBC) result in heterogenous clinical benefit with subsets of patients having disease control ranging anywhere from a few months to more than 5 years. Understanding the mechanisms that account for these differences can enable new pharmacologic approaches to convert more of these cancers into the long-term control subset. Methods: To elucidate the causal factors that underlie the observed clinical variability, we have utilized multi-omic analyses of patient samples as well as experimental modeling using a diverse cohort of ER+ breast cancers. For clinicogenomic analyses, we analyzed 467 patients with ER+/ HER2- MBC treated with first-line CDK4/6i at our institution (MSK) with detailed clinical follow annotation and follow up. For genomic/transcriptomic studies, we analyzed single cell RNA sequencing data, whole genome sequencing data, and Ki67 score from the neoadjuvant CDK4/6i containing arms in the FELINE trial (NCT02712723). Patient derived xenografts, patient derived organoids, isogenic cell lines were used to define the underlying mechanisms. Live cell imaging assays were performed by FUCCI cell cycle sensor to assess cell cycle transitions. Results: Of 467 patients from MSK cohort, 129 (27.6%) had pre-CDK4/6i loss-of-function variants in TP53, corresponding to short PFS (median PFS= 8.7 months, 95% CI: 6.6–10.3; HR = 2.12, 95% CI: 1.68 to 2.68; p = 2.64e-10). This finding was validated in two large independent clinical cohorts outside MSK. In patient derived and isogenic cell lines, p53 loss had no impact on initial drug response but promoted long-term cell outgrowth and prevented emergence of senescence phenotypes. Following cells in detailed time courses revealed the propensity of p53 mutant but not wild type cells to reenter the cell cycle after initial arrest by CDK4/6 inhibition. Gene expression analysis of RNA seq data revealed a significant positive association between TP53 mutation status and DREAM complex genes, assessed by GSEA (NES= 1.51, p = 1e-4) In models, deletion of DREAM complex component, p130-Rbl2 was found to fully recapitulate the effects of p53 loss: promoting long-term outgrowth from CDK4/6i, blocking therapy induced senescence, and promoting cell cycle re-entry. To validate these results, we analyzed the multi-omic and histologic characteristics of serial samples from the FELINE trial. Compared with WT cases, baseline TP53 LOF had a higher amount of proliferating cells at the end of treatment, measured by Ki67 > 10% (4.5% of WT cases vs. 60% of mutant cases, respectively, OR = 26.8, p = 0.014), the per cell proliferation score, measured by ssGSEA (log2FC: 0.2 vs. 2.8, respectively) as well as a higher pseudobulk expression of DREAM complex related genes (GSEA: NES = 2.0, q = 3.7e-4). Finally, to identify strategies that might facilitate stable cell cycle control of p53KO tumors, we investigated which targets of p53 regulate DREAM and identified p21. Given role of p21 in regulating both CDK4/6 and CDK2 we investigated whether CDK2 inhibitors would provide additional benefit to CDK4/6i. Addition of CDK2i was able to fully restore efficacy in p53KO lines as well as a patient derived model with TP53 mutation enabling irreversible cell cycle arrest and long-term growth suppression. Conclusion: Wild type p53 facilitates DREAM complex assembly in response to CDK4/6i in ER+ breast cancer, underlying long-term disease control. p53 loss enables cells to reenter the cell cycle and facilitates the development of CDK4/6i resistance. Combined inhibition of CDK2 with CDK4/6 represents a promising therapeutic strategy for overcoming loss of p53 and enabling long-term antitumor efficacy. Citation Format: Rei Kudo, Anton Safonov, Enrico Moiso, Catherine Jones, Hong Shao, Sharanya Nag, Selma Yeni Yildirim, Edaise M. da Silva, Qing Li, Marie Will, Atsushi Fushimi, Harikrishna Nakshatri, Andrew Koff, Britta

Year:

2025

TPS433 Background: Intensive androgen blockade with combination novel hormonal agent (NHA) + androgen deprivation therapy (ADT) appears promising as neoadjuvant therapy for high-risk localized prostate cancer (PCa) undergoing radical prostatectomy (RP). An all-oral regimen combining relugolix and darolutamide may be feasible, convenient, efficacious and exhibit no significant drug-drug interactions as neoadjuvant therapy for high-risk localized PCa and may convert patients who were initially inoperable to operable. Additionally, the rapid reversibility of castration will allow the reliable determination of post-operative PSA nadir to inform tailored adjuvant therapy. Moreover, given the convenience, this regimen may constitute an excellent backbone to develop additional combinations in future. Hence, a rationale may be made to evaluate the combination of relugolix and darolutamide as neoadjuvant therapy for 12 weeks preceding RP for high-risk localized/locally advanced PCa. Methods: This is a Phase I/Ib non-randomized, uncontrolled, open-label clinical trial evaluating the primary objective of safety and feasibility of combination darolutamide (600 mg PO BID) and relugolix (360 mg on day 1, then 120 mg PO once daily) for 12 weeks as neoadjuvant therapy preceding RP which is to be performed ≥48 hours after and within 2 weeks after completion of neoadjuvant therapy. Patients included in this study must be a candidate for RP with stage cT2-4, N0-1, high risk (defined as Gleason score (GS) ≥ 4 + 3 with ≥ 6 positive systematic biopsies (SB); GS ≥ 4 + 3 with ≥ 3 SB and prostate-specific antigen (PSA) ≥ 20 ng/mL; GS ≥ 9 in ≥ 1 SB or targeted biopsies (TB); or ≥ 2 SB or TB with continuous GS ≥ 8, each with ≥ 80% involvement), histologically or cytologically confirmed adenocarcinoma of the prostate. The Phase I component will accrue 10 patients. If ≥7 patients complete neoadjuvant combination therapy followed by RP with no severe therapy-related adverse events for up to 4 weeks following RP, the regimen is considered feasible and accrual of 20 additional patients continues in the Phase Ib expansion component of the trial to achieve a total of 30 patients. Secondary objectives include clinical response, pathologic complete response with comparison with control matched untreated group that underwent upfront RP, rate of achieving undetectable PSA nadir and testosterone recovery to normal within 8 weeks after RP and post-operative complications. Pharmacokinetic studies are performed in the Phase I component. Blood, tumor and urine are stored for future correlative studies. The trial was activated in October 2024. Clinical trial information: NCT06631521 .

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (23)

Mothaffar Rimawi

Professor, Executive Medical Director

Baylor College of Medicine

UNITED STATES
View details

Priyanka Sharma

Associate Professor

University of Kansas Medical Center

UNITED STATES
View details

Joohyuk Sohn

Yonsei University College of Medicine

SOUTH KOREA
View details

Coralia Bueno Muiño

-

SPAIN
View details

Tijana Jovanovic-Talisman

Associate Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Jee Hyun Kim

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Alexandra S. Zimmer

-

UNITED STATES
View details

Jeffrey Chang

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Sara Lopez-Tarruella

ASSOCIATE PROFESSOR

Universidad Complutense de Madrid

SPAIN
View details

Maria Ekholm

MD, PhD, Associate professor

Linköping University

SWEDEN
View details

Rachel Yoder

University of Kansas Medical Center

UNITED STATES
View details

Yuan Yuan

Scripps Research Institute

UNITED STATES
View details

Gillian Hirst

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Shane Stecklein

University of Kansas Cancer Center

UNITED STATES
View details

Junichiro Watanabe

Professor

Juntendo University

JAPAN
View details

Douglas Yee

Professor

University of Minnesota

UNITED STATES
View details

Ian F. Tannock

-

CANADA
View details

Aritro Nath

Assistant Professor

City Of Hope National Medical Center

UNITED STATES
View details

Andrew K. Godwin

University of Kansas Medical Center

UNITED STATES
View details

Patrick Cosgrove

Staff Scientist

Beckman Research Institute, City of Hope

UNITED STATES
View details

LAMORNA SWIGART

University of California, San Francisco

UNITED STATES
View details

Miguel Martin

Universidad Complutense de Madrid

SPAIN
View details

Rosalyn Sayaman

Assistant Adjunct Professor

University of California, San Francisco

UNITED STATES
View details